BioPharma

The biopharmaceutical sector of South Korea has seen a growth in innovators and drug licensing agreements by way of reaching a total deal value of almost $8 billion in 2025 year-to-date. It has emerged as a biopharma innovation hub...

The head of the Food and Drug Administration office, overseeing vaccines and gene therapy, Vinay Prasad leaves the FDA after taking over his job just three months before. Department of Health and Human Services spokesperson, Andrew Nixon, confirmed his departure...

AstraZeneca announces $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs...

There is no shred of doubt that artificial intelligence in genomics is indeed reshaping the healthcare spectrum, offering unmatched opportunities to decode the intricacies of the human genome. Apparently, in 2024, the global artificial intelligence and genomics market was valued...

Because of new ideas, concerns about safety for consumers, and government rules, the pharmaceutical business is about to enter a new era in packing. As we are passing through 2025, several significant trends are emerging that are reshaping pharmaceutical...

Selecting the appropriate contract research and manufacturing option is crucial for biopharmaceutical companies starting new initiatives related to the creation of novel antibodies. Biopharma companies are seeking reliable CDMO partnerships for specialized capacity and assistance due to the industry's growing...

The biopharmaceutical sector is driven by rising global healthcare needs, technology, technological advancements, and the imperative to remain agile in a highly regulated environment. The need for increased efficiency, cost savings, and compressed timelines has resulted in the leading...